Efficacy and Safety of Beta-adrenoceptor Inverse Agonist, Nadolol, in Mild Asthma
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the hypothesis that 18-22 week treatment with the
inverse agonist nadolol will improve airway hyperresponsiveness in patients with mild asthma,
compared to placebo.